T2 Biosystems, Inc. (0A57.L)

2,8400 -0,2880 (-9,21%) Alla chiusura: 06:34PM BST

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646
https://www.t2biosystems.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 113

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. John J. Sperzel III, B.Sc.	President, CEO & Chairman	865,5k	N/D	1963
Mr. John M. Sprague CPA	Chief Financial Officer	581k	N/D	1958
Mr. Michael Terrence Gibbs Esq.	Senior VP, General Counsel & Company Secretary	622,6k	N/D	1971
Ms. Kelley J. Morgan	Chief People Officer	N/D	N/D	1976
Mr. Brett A. Giffin	Chief Commercial Officer	N/D	N/D	1959
Dr. Roger Smith Ph.D.	Senior Vice President of Science Research & Development	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di T2 Biosystems, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.